Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The 4S study. Implications for prescribing

A J van Boven1, J Brügemann, P A de Graeff

  • 1Academic Hospital Groningen, Department of Cardiology, The Netherlands.

Drugs
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treating Microalbuminuria-Cosmetic Exercises with Urine Chemistry or Effective Reduction of Clinical Events?: Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects with Microalbuminuria. Circulation 110: 2809-2816, 2004.

Journal of the American Society of Nephrology : JASN·2023
Same author

Outcome of transcatheter aortic valve replacement in patients over 85 years of age versus patients aged 85 and younger.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2022
Same author

Prophylactic veno-arterial extracorporeal membrane oxygenation in patients undergoing high-risk percutaneous coronary intervention.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2019
Same author

Heart transplantation in the Netherlands : A national achievement.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2018
Same author

Treatment of Aortic Stenosis With a Self-Expanding, Resheathable Transcatheter Valve: One-Year Results of the International Multicenter Portico Transcatheter Aortic Valve Implantation System Study.

Circulation. Cardiovascular interventions·2018
Same author

Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation.

International journal of cardiology·2018
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Simvastatin, a cholesterol-lowering statin, significantly reduced mortality and major cardiovascular events in patients with coronary heart disease (CHD). This well-tolerated therapy offers cost-effective benefits, challenging reluctance in initiating lipid-lowering treatment.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Coronary heart disease (CHD) poses a significant health burden.
  • Cholesterol management is crucial for cardiovascular health.
  • The Scandinavian Simvastatin Survival Study (4S) investigated statin efficacy.

Purpose of the Study:

  • To evaluate the impact of simvastatin on mortality and cardiovascular events in patients with CHD.
  • To assess the cost-effectiveness and tolerability of simvastatin therapy.
  • To inform clinical practice regarding lipid-lowering therapy in CHD patients.

Main Methods:

  • The Scandinavian Simvastatin Survival Study (4S) involved patients with CHD and elevated cholesterol despite diet.
  • Participants received either simvastatin or placebo for at least 5 years.

Related Experiment Videos

  • Outcomes included mortality, nonfatal myocardial infarction, and revascularization procedures.

    • Main Results:

    • Simvastatin significantly reduced overall mortality in patients with CHD.
    • A significant decrease in nonfatal myocardial infarction was observed with simvastatin.
    • Reduced need for coronary bypass surgery or angioplasty was demonstrated.

    Conclusions:

    • Simvastatin therapy is effective in reducing mortality and major cardiovascular events in patients with CHD.
    • The therapy is well-tolerated and cost-effective, mediated by plaque stabilization and improved endothelial function.
    • Aggressive lipid-lowering therapy with simvastatin is justified in high-risk CHD patients.